Nano-Osa Biomedical

Nano-Osa Biomedical is a pre-clinical stage biotechnology company focused on developing biomimetic nanoparticle-based therapeutics for critical care and emergency medicine. Spun out of the University of California, San Diego, the company utilizes a proprietary platform that coats synthetic nanoparticle cores with natural cell membranes to create highly biocompatible delivery systems. Their lead program involves the development of artificial oxygen carriers, designed to serve as a stable and universally compatible alternative to red blood cell transfusions for treating hemorrhagic shock and trauma. By mimicking the natural oxygen-carrying capabilities of red blood cells, Nano-Osa's technology aims to provide rapid tissue oxygenation in acute settings where traditional blood products may be unavailable or impractical. The company is currently advancing its pipeline through pre-clinical validation and is supported by federal research grants.